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A B S T R A C T
In Africa, the HIV prevalence in rural areas has begun to reach levels estimated within urban settings, where
women are also more at risk for both malaria and intestinal parasitic infections. The objective of this review is to
assess whether concomitant infections with malaria and/or helminthic diseases have an impact on cervical
disease progression in women on HAART.
This scoping review was conducted in August 2018. To conduct this scoping review, we searched the relevant
studies in electronic databases such as PUBMED, Global Health, EMBASE, CINAHL and SCOPUS published in the
year between 1960 and 2018 using the following search terms HAART AND malaria OR Helminth and Female
OR women.
Eight studies qualified for this review. The literature underscores the need for women on HAART with
multiple co-infections to use adjuncts to retain immune recovery and undetectable HIV viral load, to reduce risk
of cervical disease progression. A trend for higher risk of CIN3+ in HIV+ women reporting recent malarial
infection was observed in one study.
Given the public health impact of synergistic interactions between malaria and helminthic infections in HIV/
HPV co-infected women on HAART, it is urgent that these interactions are elucidated.
1. Background
It is estimated that two-thirds of the 36.9 million people living with
HIV/AIDS worldwide, reside in the sub Saharan Africa region, with a
rising majority in rural areas.(Joint United Nations Programme on HIV/
AIDS (UNAIDS) and the World Health Organization (WHO), 2009) In
2007, the World Health Organization (WHO) included Invasive Cervical
Cancer (ICC) to stage “4” of the HIV/AIDS classification of its clinical
staging and case definition of HIV for resource-constrained settings.
(WHO Department of Immunization, Vaccines and Biologicals, World
Health Organization; Geneva, 2007) In sub Saharan African women,
ICC is the second most common cancer and leading cause of cancer
death.(Arbyn et al., 2011) (Ferlay et al., 2010)
High risk Human papillomavirus (HR/HPV), a sexually transmitted
infection (STI), has been shown to be present in 99.7% of cervical
cancers worldwide.(Walboomers et al., 1999) Co-infections leads to
greater HIV replication and disease progression through immune acti-
vation of cellular mechanisms, rendering the CD4+T lymphocyte cells
susceptible to HIV increased viral load.(Celum, 2004) (Mercader et al.,
2001) Available data suggest that HIV-positive women with squamous
abnormalities detected on their Pap smears have a significantly higher
HIV viral load than women with negative Pap smears. (Cardillo et al.,
2001) (Agaba et al., 2009) (Swende et al., 2012)
Three WHO global recommendations for cervical cancer primary
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and secondary prevention are likely to have an impact on women in
resource-poor settings. These include: firstly, offering HPV vaccine
against HPV genotypes 16 and 18, (which have the greatest oncogenic
potential, accounting for about 70% of all ICC(Muñoz et al., 2003)), to
girls at ages 9–13 naïve to the targeted types; secondly, a “screen and
treat” approach in resource poor settings, in which access to Visual
Inspection with 3–5% acetic acid (VIA) or, if possible, HPV testing
followed soon or immediately by treatment of detected precancerous
lesions(WHO, 2014); and thirdly, the INSIGHT START Study Group
et al., 2015 revision of its recommendations to embark on Highly-Ac-
tive Antiretroviral Treatment (HAART) regardless of WHO clinical stage
classification for HIV or CD4 count.(WHO (WHO, 2013) WHO issues
new HIV recommendations calling for earlier treatment accessed on,
2016) Whilst in some European populations a positive association of
HIV infection and ICC has been documented in women on HAART,
(Franceschi et al., 2003) (Dal Maso et al., 2001) the picture is less clear
in Africa due to conflicting evidence,(Franceschi et al., 2003) (La Ruche
et al., 1998) (Hawes et al., 2003) (Adjorlolo-Johnson et al., 2010)
(Odida et al., 2011) (Kahesa et al., 2008) which in turn suggests that
there may be other risk factors at play.
The use of HPV tests for cervical cancer prevention is expected to
reduce the frequency of screening and “once a woman has been
screened negative, she should not be rescreened for at least 5 years, but
should be rescreened within ten”(New WHO Guide to Prevent and
Control Cervical Cancer [Internet], 2014). However, there is currently a
paucity of evidence to support the adequacy of this guideline in HIV-
infected women living in Sub-Saharan Africa, Asia and South America,
where a meta-analysis of case-control studies have indicated sub-
stantially higher risks of cervical cancer among women in lower social
class groups.(Parikh et al., 2003) In sub-Saharan Africa, co-infected
HIV/HPV infected women living in rural areas are also at higher risk of
malaria and helminthic diseases, all ‘diseases of poverty’,(Worrall et al.,
2005) (Stevens, 2004) where inequitable access to HIV, cervical cancer,
malaria and helminthic interventions increase the vulnerability of the
poorest.(Worrall et al., 2005)
Helminthic infections may dampen the protective Th1 responses
responsible for cell-mediated immunity against bacterial, protozoal,
viral, and intracellular parasitic infections, whereas in a Th2 response,
helper cells mediate antibody-dependent immunity against extra-
cellular parasites including intestinal helminths.(Rafi et al., 2012) The
polarizing of the immune response towards Th2 and the ensuing re-
duction of the Th1 response modifies responses to viruses, including
hepatitis C virus(Farid et al., 2005) and STDs, which in turn increases
susceptibility to HIV and hastens its progression by increasing HIV viral
load. (Farid et al., 2005) (Lamb et al., 2005) (Marsh & Kinyanjui, 2006)
This in turn may reduce the potency of some vaccines(van Riet et al.,
2007) and lead to cervical disease progression.
Malaria is associated with strong CD4 cell activation and upregu-
lation of Th1 pro-inflammatory cytokines.
Previous studies have shown evidence of pathological interactions
between HIV and malaria, especially in areas where they are co-en-
demic.(Onyenekwe et al., 2007) (Nkuo-Akanji et al., 2008) (Diego
et al., 2011) HIV infection has been reported to roughly double the risk
of malaria parasitemia and increase the frequency and severity of
clinical malaria.(Francesconi et al., 2001) (French et al., 2001) (Laufer
et al., 2006) (Whitworth et al., 2000)Furthermore, a systematic review
reported that clinical malaria incites HIV replication, which in turn
hastens immune system decline and HIV disease progression to AIDS.
(Flateau et al., 2011) (Reina & Potter, 2006) As a corollary, this may
result in cervical disease progression.
In sub Saharan Africa, the four diseases converge disproportionately
in rural areas, (Ivan et al., 2013) with a recent study in Kenya reporting
that only 16% of women were uninfected by either or both P. falciparum
and helminth infection at the time of delivery, with hookworms ac-
counting for 36–46% of all helminthic infections.(Fairley et al., 2013)
The objectives of this scoping review are two-fold: firstly, it assesses
whether there is an association between malaria and/or helminthic
diseases coinfections and cervical disease progression in women who
have initiated HAART; secondly, it outlines epidemiological, clinical
research gaps that will need to be addressed to design programmes that
enhance prevention of malaria and helminthic infection in women with
HIV and HPV.
2. Methods
We conducted this scoping review based on a pre-defined search
protocol that conformed to the criteria set out by the PRISMA statement
(PRISMA statement, 2016) We chose a scoping review as a research
format, which has been described as a process of mapping the existing
literature or evidence base as appropriate, to address the research
questions included in this study. We searched the relevant studies in the
following electronic databases, PubMed, Global Health, EMBASE, CI-
NAHL and SCOPUS were searched until August 2018.
2.1. Search terms
The following search terms were used HAART AND malaria or
helminth AND Female OR Women. See Annex for full search term
strategy
2.1.1. Inclusion criteria
Article selection criteria included any methodologically-sound
clinic-based randomized-controlled trials (RCTs), meta-analysis/sys-
tematic reviews and observational studies. We excluded publications
such as case reports, articles that did not include combination anti-
retroviral therapy or did not report data by HAART users.
All references of retrieved articles were further searched for iden-
tification of other potential articles. Articles were title-screened and
then abstract-screened. Articles that appeared as relevant from the first
screening were read in full.
2.1.2. Study selection
We considered the following four components (Population,
Intervention, Comparison, Outcome - PICO) to assess and categorize
studies to be included in this review.
2.1.2.1. Population. The population of interest is sub Saharan women
infected with HIV-HPV and malaria or helminthic infections who are on
HAART. In addition, studies in which HIV viral load/ CD4 count were
used as proxies for cervical cancer progression were eligible.
2.1.2.2. Intervention. The intervention examined in this study is the
administration of HAART.
2.1.2.3. Comparison. Various comparisons were explored on the
episodes (or not) of malaria and helminthic infection in women on
HAART versus women not on HAART.
2.1.2.4. Outcome(s). 1) Change in HIV viral load or/and
immunological parameters, 2) cervical dysplasia or the progression of
cervical disease, and 3) incidence/prevalence of malaria/helminthic
infections.
3. Results
On August 23th, 2018 we retrieved 585 articles, of which 43 were
duplicates. After title/abstract screening, 20 were eligible for full text
screening. Finally, 8 studies were included for this review (see flow-
chart).
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3.1. Study population
The sample size ranged from 342 to 5379 HIV-malaria/or hel-
minthic diseases infected women and 476 HIV- HPV- malaria triple
infected women on HAART. See Table 1.
3.2. Study design
Two studies were cross sectional, one was retrospective cohorts, two
were RCTs and three were prospective cohort study designs.
3.3. Geographical location
Of the eight studies identified for the current review, one study each
was carried out in Nigeria(Omoti et al., 2013) and Kenya(Polyak et al.,
2016). The remaining studies were conducted in Uganda (2)(Ekwaru
et al., 2013) (Lankowski et al., 2014) and Rwanda (4).(Ivan et al., 2015)
(Ivan et al., 2013) (Ivan et al., 2012)
3.4. Co parasitic infections
3.4.1. Malaria infections
Only one study has been identified to explore the direct association
between abnormal cytology in dually infected HIV-HPV women and
malaria. In Rwanda, (Anastos et al., 2010) found that recent malarial
infections had a significant positive association with CIN3+ in HIV
+/HPV+ women, after adjusting for CD4 count, (OR: 3.3; 95% CI:
0.8–13.3). This was the first report of any direct evidence that malarial
infections might contribute to the risk of cervical pre-cancer and cancer.
(Swende et al., 2012)
Ekwaru et al. (Uganda, 2013) suggested that women on HAART
with undetectable HIV viral load may still experience increased HIV
viral load to detectable levels and decline in CD4 T cell counts during
episodes of WHO Stage 3 or 4 illnesses and malaria. (Reina & Potter,
2006)This difference remained statistically significant (OR: 3.8; 95%
CI: 1.73–8.39), after adjusting for the non-independence of repeated
observations within an individual, gender, duration of HAART, age,
Body Mass Index at baseline, first-line HAART regimen, HAART ad-
herence preceding the interval and previous three month CD4 T cell
count in 1094 HIV-1-infected adults.(Reina & Potter, 2006) Similarly,
Omoti et al. (Omoti et al., 2013) in Nigeria observed a significant as-
sociation between CD4+ cell count and significant parasitemia
(P < .0001) and the odds of having malaria parasitemia increased with
advancing clinical stage of HIV infection and this was statistically sig-
nificant (P= .002, OR=2.32) underscoring the importance of early
HAART initiation to prevent a subsequent HIV viral load and as a
corollary cervical disease progression. This study group included 342
HIV+ adults with HAART, although it is not known whether the viral
load increased to detectable levels.(PRISMA statement, 2016)
Polyak et al. (Polyak et al., 2016) undertook a RCT conducted
among adults on HAART with evidence of immune recovery (ART for
≥18months and CD4 count> 350 cells/mm3) to determine whether
discontinuation of Co-trimoxazole (CTX) was non-inferior to continued
CTX prophylaxis in decreasing morbidity for some diseases, including
malaria. (van Riet et al., 2007) Despite having received HAART for a
median of> 4 years and having immune reconstitution, adults who
stopped CTX prophylaxis had significantly higher incidence of the
combined morbidity/mortality endpoint, driven by malaria morbidity
(IRR=2.27, 95% CI: 1.52–3.38).(Rafi et al., 2012) These results, while
not being able to assess the role of HAART in preventing malaria
morbidity or mortality, show the importance of CTX treatment con-
tinuation in HIV patients in malaria-endemic contexts.
3.4.2. Helminthic infections
Two studies have shown how women seem to benefit most from
empiric deworming. It is therefore possible that Albendazole (ABZ)
therapy has a more significant effect on the immune system respon-
siveness of HIV-infected subjects in the presence of HAART. (Lankowski
et al., 2014)reported that empiric deworming of HIV-infected in-
dividuals on HAART conferred no significant generalized benefit on
subsequent CD4 count recovery, with a change in CD4 over time of
42.8; 95% CI:−2.1–87.7)in the first year on ART and − 9.9; 95% CI:
−24.1-4.4 after the first year of ART.(Stevens, 2004) However, in a
sub-analysis by gender, during the first year of ART deworming was
associated with a significantly greater rise in CD4 count with an in-
crease of 63.0; 95% CI: 6.0–120.1 in women.(Stevens, 2004) However,
it is noted that the female study population differed significantly from
males with respect to several important baseline characteristics in the
model, including age, tuberculosis co-infection and baseline CD4 count.
These favorable findings in women are congruent with (Ivan et al.,
2015)) findings from a longitudinal study where antihelminthic therapy
significantly reduced detectable viral load and increased CD4 counts
and hemoglobin levels in 980 pregnant, HIV-infected women with
helminth coinfections receiving HAART.(van Riet et al., 2007)
Two studies in Rwanda suggested a differential impact of certain
HAART combinations on helminthic and the prevention of malaria in-
fection. Ivan et al. (Ivan et al., 2013) undertook a prospective study on
980 pregnant patients recruited from health centers in rural and peri-
urban locations in the central and eastern provinces of Rwanda. Certain
HAART combinations, including the Tenofovir (TDF)- Lamivudine
(3TC)- Nevirapine (NVP) (OR: 3.47; 95% CI: 2.21–5.45); Stavudine
(D4T)-3TC-NVP (OR: 2.47; 95% CI 1.27–4.80) and (Zidovudine) AZT-
NVP (OR: 2.60; 95% CI: 1.33–5.080) regimens, yielded higher helminth
infection rates than the AZT-3TC-NVP regimen. HAART had no effect
on the risk of malaria. (Walboomers et al., 1999)
This finding is contradictory to the Ivan et al. (Ivan et al., 2012)
findings from a cross sectional study of 328 HIV-infected pregnant
women, which demonstrated that specific HAART regimens, such as
d4T, 3TC, NVP regimen had a reduced risk of T. trichiura infection (OR:
0.27, 95% CI: 0.10–0.76) and malaria–helminth dual infection (OR:
0.29, 95% CI: 0.11–0.75) compared to those receiving AZT, 3TC, NVP.
(Whitworth et al., 2000)
4. Discussion
Indirect evidence on cervical dysplasia progression suggests an anti-
helminthic effect of certain HAART regimens (potentially including the
indirect impact of Co-trimoxazole treatment on malaria) and of a de-
worming adjunct, increasing HAART effectiveness in women. This un-
derscores the need to consider an adjunct in order to improve positive
impact of HAART. Moreover, there is evidence that episodes of malaria
among patients on HAART were associated with detectable HIV viral
load levels or reduced CD4 count and an adjunct is needed to reduce
malaria-related morbidity. The only study on HIV-HPV- malaria co-in-
fected women found a statistically significant association between
malaria and CIN 3+. The mechanisms by which malarial infections
could increase the risk of CIN3+ are unknown, but might include ad-
ditional challenges to the already compromised immune system of HIV
+ women. HIV, HPV and malarial infections are highly prevalent in
vast areas of sub Saharan Africa, and any increased risk of CIN3+ as-
sociated with malaria could result in a substantial attributable risk,
although the percentage of women on HAART is unknown.
4.1. Strengths and limitations
One strength of our review is the relatively large sample sizes of the
included studies as well as their prospective nature, which would allow
the causal criterion of temporality to be fulfilled. However, our findings
should be seen in light of the scarcity of studies specifically exploring a
direct association between malaria and/or helminthic disease and cer-
vical disease progression. Furthermore, our interpretations inferences
may be further restricted as literature suggests that the impact of
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helminth infection on HIV-1 may be species-specific.(Brooker et al.,
2009)
4.2. Clinical and public health impact
One main aspect to consider is that high endemic settings for ma-
laria are also settings where women are more at risk for helminthic
infections due to less access to fresh water, adequate sewage and gen-
eral living and hygienic conditions. In rural areas with socio economic
deprivation, HIV-infected women are also likely to be infected with
concomitant malaria and helminthic infections. In a rural study in
Nigeria, out of the 205 subjects examined, 51.9% of the cases har-
boured various parasites with helminthes.(Jegede et al., 2014)
Moreover, in these settings, other services such as family planning
and antenatal care may also be scarce, with potential negative spirals, if
women have more difficulties in preventing unwanted pregnancies.
This problem is further compounded by less access to antenatal care
and malaria prevention during pregnancy, leading to a higher risk of
malaria and helminthic infections during pregnancy, resulting in a
potential higher burden.
These findings, uncertainties and extreme vulnerabilities of socio-
economically deprived HIV-HPV co-infected rural women reveal the
need for further research, which would determine the benefits for an
integrated cervical prevention management approach, coupled with
enhanced malaria and helminthic infections targeting this population.
This may build on the integrated TB/HIV prevention model already in
place, premised on the known correlates of HIV disease progression and
co-morbid infection.
4.3. Epidemiological and clinical research gaps
In order to determine the effectiveness of a triage-based secondary
cervical cancer prevention program in HIV-HPV infected women on the
basis of malaria and/or helminthic disease co-infection, there are some
clinical and epidemiological research gaps which will need to be elu-
cidated.
4.3.1. Malaria and severe abnormal cytology
Given that HIV, HPV and malarial infections are highly prevalent in
vast areas of sub Saharan Africa, and any increased risk of CIN3+ as-
sociated with malaria could result in a substantial attributable risk, the
mechanisms by which malarial infections could increase the risk of CIN
3+ need to be elucidated. Prospective studies should be undertaken to
enhance cervical cancer prevention in HIV-malaria co-infected women.
4.3.2. Helminthic infections and cervical disease progression
The potential variable geographic distribution in the continent be-
tween different species of soil-transmitted helminths should be con-
sidered, and trials to evaluate species-specific effects are required along
with the long–term clinical outcomes following deworming.
Prospective studies are necessary to explore the clinical impact that
helminthic infections have on HIV and cervical disease progression in
women initiating HAART at different levels of immunosuppression.
These may test whether enhanced preventive services for malaria and
other parasitic infections slow down progression of cervical disease.
Furthermore, the epidemiological, clinical, and biological basis of the
differential impact of HAART with deworming as adjunct in women as
well as the antihelminthic effect of some ART combinations warrants
further studies.
4.3.3. Concomitant malaria and helminthic infections
In light of the geographic and socioeconomic overlap of immune
modulating malaria and helminnthic infections, their synergistic in-
teractions on cervical disease progression in HIV-HPV infected women
need to be elucidated.
4.3.4. Prophylactic vaccines
Determination of a tailored triage-based secondary cervical cancer
prevention program for HIV- infected women on HAART will also de-
pend on the efficacy of the HPV prophylaxis vaccine within this po-
pulation. Studies should explore differences between levels of HPV 16/
18 antibodies after administration of the vaccine among HIV infected
women exposed to malaria/and or helminthic infections.
4.3.5. Public health impact of multiple concomitant infections
The prevalence of HIV, HPV, malaria and chronic helminthic in-
fections should be characterized in sub Saharan Africa and their sy-
nergistic interactions in the post HAART era better elucidated to cal-
culate the Population Fraction attributable to cervical disease
progression. On the basis of this impact, the effectiveness of an in-
tegrated management for cervical cancer prevention, akin to the IMCI
model advocated by the WHO should be assessed.
5. Conclusion
Our review underscores the need for better elucidation of the sy-
nergistic interactions between HIV-HPV and malaria/helminthic dis-
eases. Given the extensive overlap in the geographic distribution of
malaria, helminthic and HIV-HPV co-infections, even the currently
scant evidence on synergistic interactions may have an enormous public
health importance in sub-Saharan Africa, where malaria and multiple
helminth species are also endemic.
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